GLPwatch
Papers (9189)
Page 103 of 154, ranked by citation count.
- Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.
- A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
- Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
- The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.
- Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
- Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
- Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review.
- Retatrutide: a triple incretin receptor agonist for obesity management.
- Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.
- Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
- Development and characterization of exendin-4 loaded self-nanoemulsifying system and <i>in vitro</i> evaluation on Caco-2 cell line.
- [Current State of Pharmacotherapy in Obesity].
- A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
- Noninvasive in vivo Assessment of the Re-endothelialization Process Using Ultrasound Biomicroscopy in the Rat Carotid Artery Balloon Injury Model.
- Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
- One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
- The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice.
- Tirzepatide (Zepbound) for chronic weight management.
- Regulation of feeding and therapeutic application of bioactive peptides.
- Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
- Liraglutide for Adolescents with Obesity.
- Weight Loss Pharmacotherapy: Current and Future Therapies.
- Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.
- Smoke or fire? Acute pancreatitis and the liraglutide trials.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.
- Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
- UK regulator warns public after seizing hundreds of fake Ozempic pens.
- Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
- A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.
- A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression.
- [Effects of liraglutide on the expression of local renin-angiotensin system, transforming growth factor-β1 and collagen type III in pulmonary tissue of diabetic rats].
- Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes.
- Drugs for type 2 diabetes.
- Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- A Conserved Hydrophobic Moiety and Helix-Helix Interactions Drive the Self-Assembly of the Incretin Analog Exendin-4.
- Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.
- Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis.
- Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.
- Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with <sup>111</sup>In-labeled exendin-4.
- The Expression of RAAS Key Receptors, <i>Agtr2</i> and <i>Bdkrb1</i>, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome.
- Exendin-4 promotes ischemia-reperfusion flap survival by upregulating Gpx4 to inhibit ferroptosis.
- Patient involvement in drug licensing: a case study.
- Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
- Review of pharmacotherapy options for the management of obesity.
- Semaglutide for Weight Loss.
- The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway.
- The efficacy of liraglutide combined with intragastric balloon on weight loss.
- Effects of exendin-4 on colonic motility in rats and its underlying mechanism.
- Anorectic state of obesity medications in the United States. Are leaner times ahead?
- [A 45-fold liraglutide overdose did not cause hypoglycaemia].
- Liraglutide-associated depression in a patient with type 2 diabetes: A case report and discussion.
- Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating β-secretase and γ-secretase and alleviating oxidative stress in HT-22 cells.
- Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
- Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.
- Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue.
- Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.